4//SEC Filing
ADELMAN DANIEL C MD 4
Accession 0000899243-20-028171
CIK 0001631650other
Filed
Oct 13, 8:00 PM ET
Accepted
Oct 14, 4:15 PM ET
Size
18.7 KB
Accession
0000899243-20-028171
Insider Transaction Report
Form 4
ADELMAN DANIEL C MD
Chief Medical Officer
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2020-10-13$14.87/sh−70,000$1,040,900→ 0 totalExercise: $19.63→ Common Stock (70,000 underlying) - Disposition from Tender
Common Stock, $0.0001 par value
2020-10-10$34.50/sh−41,464$1,430,508→ 0 total - Disposition to Issuer
Common Stock, $0.0001 par value
2020-10-13$34.50/sh−22,343$770,834→ 0 total - Disposition to Issuer
Stock Option (right to buy)
2020-10-13$23.05/sh−135,068$3,113,317→ 0 totalExercise: $11.45→ Common Stock (135,068 underlying) - Disposition to Issuer
Stock Option (right to buy)
2020-10-13$0.43/sh−56,250$24,188→ 0 totalExercise: $34.07→ Common Stock (56,250 underlying) - Disposition to Issuer
Stock Option (right to buy)
2020-10-13$10.78/sh−71,250$768,075→ 0 totalExercise: $23.72→ Common Stock (71,250 underlying) - Disposition to Issuer
Stock Option (right to buy)
2020-10-13$10.69/sh−52,500$561,225→ 0 totalExercise: $23.81→ Common Stock (52,500 underlying)
Footnotes (3)
- [F1]Disposed of to SPN MergerSub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated August 29, 2020, by and between the Issuer, Societes des Produits Nestle S.A., ("Nestle"), and Merger Sub (the "Merger Agreement"), commenced a tender offer to acquire any and all of the outstanding shares of the Issuer's common stock (other than those shares owned by Nestle and its affiliates) at a purchase price of $34.50 per share (the "Offer Price").
- [F2]Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") that was outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") vested in full, terminated, and was converted into the right to receive a cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of common stock subject to the RSU.
- [F3]Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.
Documents
Issuer
Aimmune Therapeutics, Inc.
CIK 0001631650
Entity typeother
Related Parties
1- filerCIK 0001222037
Filing Metadata
- Form type
- 4
- Filed
- Oct 13, 8:00 PM ET
- Accepted
- Oct 14, 4:15 PM ET
- Size
- 18.7 KB